Molecular Analysis-Based Treatment Prospects and Innovations for Diffuse Large B-Cell Lymphomas
Keywords:
Diffuse Large B-Cell Lymphoma (DLBCL), Molecular Targeted Therapy, CAR-T Cell Therapy, Bispecific Antibodies, BTK InhibitorsAbstract
This study explores the treatment prospects and innovations in diffuse large B-cell lymphoma (DLBCL) based on molecular analysis. We analyzed 110 patients diagnosed with DLBCL, conducting immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) to classify molecular subtypes and identify key genetic mutations. Our research focused on assessing the efficacy of traditional R-CHOP therapy compared to novel targeted treatments, including CAR-T cell therapy, bispecific antibodies, and BTK inhibitors. The results showed that molecular profiling significantly impacts treatment outcomes, with high-risk genetic subtypes responding better to personalized therapies. Double-hit and triple-hit lymphomas demonstrated poor response to standard therapy but improved survival with CAR-T treatment. Targeted drugs such as EZH2 inhibitors and immune checkpoint inhibitors also showed promising results in refractory cases. This study highlights the importance of molecular diagnostics in guiding treatment strategies and emphasizes the need for further research to optimize individualized therapy for DLBCL patients.
References
Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-58. doi:10.1056/NEJMra2027612.
Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular Subtypes of DLBCL Are Associated with Distinct Pathogenic Mechanisms and Outcomes. Nat Med. 2020;26(5):679-90. doi:10.1038/s41591-020-0894-z.
Nowakowski GS, Chiappella A, Gascoyne RD, Davis RE, Fayad L, Yoon DH, et al. ROBUST: Lenalidomide Plus R-CHOP Versus Placebo-R-CHOP in Previously Untreated ABC-Type DLBCL. J Clin Oncol. 2021;39(12):1317-28. doi:10.1200/JCO.20.02551.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;380(1):45-56. doi:10.1056/NEJMoa1804980.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Primary Analysis of ZUMA-7: A Phase 3 Study of Axicabtagene Ciloleucel vs Standard-of-Care Therapy in Second-Line Relapsed/Refractory DLBCL. Lancet. 2022;399(10343):36-46. doi:10.1016/S0140-6736(21)01788-X.
Thieblemont C, Tilly H, da Silva MG, Casasnovas RO, Fruchart C, Morschhauser F, et al. Lenalidomide Maintenance Compared with Placebo in Responding Elderly Patients with DLBCL: The REMARC Trial. J Clin Oncol. 2020;38(3):248-57. doi:10.1200/JCO.19.01532.
Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Epcoritamab, a Bispecific Antibody Targeting CD3 and CD20 in Relapsed or Refractory B-Cell Lymphoma. J Clin Oncol. 2022;40(8):839-48. doi:10.1200/JCO.21.01859.
Wang M, Munoz J, Goy A, Locke FL, Jacobson C, Hill BT, et al. Zanubrutinib for the Treatment of Relapsed/Refractory DLBCL: A Phase 2 Study. Blood Adv. 2021;5(18):3625-35. doi:10.1182/bloodadvances.2021004846.
Jacobson C, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Odronextamab (REGN1979) in Relapsed or Refractory DLBCL and FL: Phase 1 Results. Blood. 2021;137(21):2884-94. doi:10.1182/blood.2020009746.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma. Lancet. 2020;396(10254):839-52. doi:10.1016/S0140-6736(20)31366-0.
Herrera AF, Goy A, Mehta A, Kim WS, Bouabdallah R, Cordoba R, et al. Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL. J Clin Oncol. 2022;40(8):912-21. doi:10.1200/JCO.21.01242.
Munoz J, Wang M, Cheson BD. Emerging BTK Inhibitors for the Treatment of B-Cell Malignancies. Clin Lymphoma Myeloma Leuk. 2021;21(11):733-41. doi:10.1016/j.clml.2021.06.008.
Liu Y, Barta SK. Prognostic and Predictive Biomarkers in Diffuse Large B-Cell Lymphoma: Current Status and Future Directions. J Immunother Precis Oncol. 2020;3(3):82-94. doi:10.36401/JIPO-20-005.
Ribrag V, Bossard C, Garciaz S, Morschhauser F, Ghesquieres H, Pica GM, et al. Temsirolimus Plus Rituximab in Relapsed/Refractory DLBCL: A Phase 2 Study. Blood Cancer J. 2021;11(12):195. doi:10.1038/s41408-021-00591-x.
